FDA approves Zurzuvae, a drug for adults experiencing severe depression related to childbirth or pregnancy.
on Friday granted approval of the drug, Zurzuvae, for adults experiencing severe depression related to childbirth or pregnancy. The pill is taken once a day for 14 days.
Postpartum depression affects an estimated 400,000 people a year, and while it often ends on its own within a couple weeks, it can continue for months or even years. Standard treatment includes counseling or antidepressants, which can take weeks to work and don’t help everyone.Sign up for NBC Bay Area’s Housing Deconstructed newsletter.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
A Game-Changing Pill For Postpartum Depression Was Just Approved By The FDAThe FDA has approved Zurzuvae, the first-ever pill for treating postpartum depression. Here’s how it works.
続きを読む »
First-ever pill for postpartum depression is up for FDA approval this weekThe FDA is expected to decide by Saturday whether to approve the first-ever pill for postpartum depression. If approved, it will become the first treatment that can be taken at home.
続きを読む »
First-ever pill for postpartum depression is up for FDA approval this weekThe Food and Drug Administration is expected to decide by Saturday whether to approve the first-ever pill for postpartum depression.
続きを読む »
FDA approves first postpartum depression pillFederal health officials have approved the first pill specifically intended to treat severe depression after childbirth, a condition that affects thousands of new mothers in the U.S. each year.
続きを読む »
First Pill for Postpartum Depression Is Approved by FDAThe pill, to be taken daily for at least two weeks, significantly reduced postpartum depression among new mothers in a recent trial.
続きを読む »
FDA approves first postpartum depression pillFederal health officials have approved the first pill specifically intended to treat severe depression after childbirth, a condition that affects thousands of new mothers in the U.S. each year.
続きを読む »